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ABSTRACT
Women with antiphospholipid syndrome (APS) have circulating antiphospholipid
antibodies (aPL) and are at risk for recurrent pregnancy loss and late pregnancy
complications due placental dysfunction. Recent research has demonstrated that aPL
directly alter human first trimester trophoblast function by up-regulating
inflammatory cytokines, limiting cell migration, and altering angiogenic factor
production. Due to their anti-inflammatory properties, Statins have been tested both
in vitro, using human trophoblast, and in vivo, using a mouse model, for the
treatment of APS-associated pregnancy complications and preeclampsia. In vivo
mouse studies showed that statins prevent aPL- mediated fetal loss, whereas in vitro
human studies suggest that statins, like pravastatin may compromise normal
trophoblast function and viability. Therefore, the objective of this study was to test
the hypothesis that pravastatin prevents the effects of aPL-on human first trimester
trophoblast function. The human first trimester trophoblast cell line, HTR8, and first
trimester trophoblast primary cultures were incubated with or without an aPL in the
presence or absence of pravastatin. Cytokine and angiogenic factor secretion were
measured by ELISA and multiplex analysis. Cell migration was measured using a
colorimetric two-chamber migration assay. Pravastatin significantly augmented the
aPL-induced up-regulation of IL-8, IL-1 and sEndoglin secretion by HTR8 cells, but
had no effect on aPL-induced up-regulation of VEGF, PlGF and GRO-.
Furthermore, pravastatin alone limited basal HTR8 cell migration, and did not
mitigate the adverse effect of aPL on trophoblast migration. However, Pravastatin
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had no effect on aPL-mediated changes in primary first trimester trophoblast
function. These findings demonstrate that pravastatin does not prevent the effects of
aPL antibody on first trimester trophoblast cell function, and so may not be
beneficial as a therapeutic for pregnant APS patients. However, it did not have any
negative effects on basal primary cell function and, therefore, may be safe to use in
patients at high risk for preeclampsia.
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INTRODUCTION

Antiphospholipid syndrome (APS), also known as Hughes syndrome, is a systemic
autoimmune disease that is diagnosed when a person with laboratory evidence of
persistent circulating antiphospholipid (aPL) antibody presents clinically with
vascular thrombosis and/or pregnancy morbidity [1, 2, 3, 4]. Persistent circulating
aPL refers to the presence of aPL on at least two separate occasions that are at least 6
weeks apart [1]. The pregnancy morbidities in pregnant APS patients vary and
include recurrent fetal loss (rate can be up to 90% when no specific treatment is
given [5]), as well as late term complications such as preeclampsia, HELLP
Syndrome (Hemolytic anemia, Elevated Liver enzymes and Low Platelet count),
premature birth and intrauterine growth restriction (IUGR) [6]. However, the
pregnancy morbidities required for the diagnosis of APS are history of unexplained
recurrent fetal loss, or premature birth secondary to preeclampsia or any other
feature suggestive of placental insufficiency [2]. In addition to obstetric
complications, APS patients in general are at significant risk of vascular thrombosis;
hence it is an alternative clinical requirement for diagnosis of the disease. In fact,
overall, thrombotic complications are the main source of complications in APS
patients [7] as they are 3-10 times more likely to have thrombosis than people
without aPL antibodies [1]. Vascular thrombosis can be both arterial (especially
cerebral vessels) and venous (especially the deep veins of the lower extremities).
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APS is caused by a group of heterogenous autoantibodies which, although they are
called antiphospholipid antibodies, actually bind to phospholipid-binding proteins
such as Annexin V, Protein C, Prothombin and beta 2-glycoprotein 1 (2GPI) [2, 3, 8].
The clinically significant aPL used in the diagnosis of APS are either ELISA-detected
IgG or IgM anticardiolipin (aCL) and/or anti-2GPI antibodies or a functional assay
for lupus antigoagulant (LA) that determines its anticoagulant activity against 2GPI
and prothrombin [2]. The LA test is most commonly used for diagnosis. These
antibodies are present in 7- 25% of women with recurrent fetal loss [2, 3]. Though
lupus anticoagulant is one of the antibodies used in diagnosis of APS, and one third
of patients with systemic lupus erythematous (SLE) have aPL and may in fact meet
the criteria for APS, it is important to note that SLE is a separate entity from APS;
there are specific and different set of criteria for diagnosis of SLE [9]. APS can be
present in the absence of any other autoimmune disease (called primary APS in such
scenario), or in the presence of another autoimmune disease such as SLE, in which
case it is designated as secondary APS.

Of the known phospholipid-binding proteins, 2GPI is the most clinically significant
in the pathology of APS and all the afore mentioned aPL antibodies (LA, aCL and
anti-2GPI) can bind to it. However, one can have LA and aCL without 2GPI
activity because LA can also bind to prothrombin, and while 2GPI is a cofactor for
binding of aCL in APS, there is also 2GPI-independent aCL that is associated with
infectious process [2]. Beta 2 glycoprotein 1 is a highly glycosylated protein with a
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lysine-rich domain that interacts with and is immobilized when it binds to
negatively charged membrane phospholipids such cardiolipin and phosphatidyl
serine [2, 8]. The formation of an aPL-2GPI complex increases the affinity of 2GPI
for membrane phospholipid [2].

While most cells will only bind exogenous β2GPI on their cell surface under
pathologic, stimulatory or apoptotic conditions, when the inner negatively charged
phospholipids become exposed onto the outer leaflet of the plasma membrane [8, 10,
11, 12], the trophoblast (cells of the placenta) is unusual in that it normally expresses
these anionic phospholipids on its cell surface [8, 13, 14, 15]. This is due to
trophoblast cell’s high level of tissue remodeling involving high levels of
proliferation and differentiation as part of normal placentation [8]. For review,
normal placentation begins with the blastocyst adhering to the uterine wall. This is
followed by invasion of the endometrium by a subset of trophoblast cells called
cytotrophoblasts, the trophoblast stem cell, which undergoing proliferation to
regenerate

the

functional

cells

that

constitute

the

placenta

[16].

These

cytotrophoblasts can take two differentiation routes: 1) to undergo fusion to form
the outer syncytiotrophoblast layer of the placenta; and 2) invading deep into the
maternal decidual tissue, and here differentiating into extravillous trophoblast cells.
These extravillous trophoblast cells then proceed to invade the maternal spiral
arteries and remodel these vessels, differentiating into endovascular trophoblast
cells and replacing the maternal endothelial cells. This transformation of the
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maternal vasculature results in increased blood flow into the placental intervillous
space. The presence of anionic phospholipids on the outer leaflet of the trophoblasts
has been linked to their abilities to undergo their normal functions, including fusion
to form the syncytium [2, 15, 17]. Therefore due to the presence of anionic
phospholipids on its outer leaflet of the cell membrane, the trophoblast can bind
exogenous β2GPI on its cell surface under normal physiological conditions.
Additionally, trophoblast normally produces its own 2GPI, and in vivo, there is
evidence that β2GPI localizes to the surface of the extravillous trophoblast cells that
invade the decidua, and to the syncytiotrophoblast cells that are in direct contact
with maternal blood [8]. These reasons explain the tropism of aPL for the placenta
[2, 4, 8] and is further supported by the laboratory finding that passive transfer of
human aPL into pregnant mice leads to its disappearance from peripheral
circulation and accumulation in the placenta [2]. The fact that the placenta is a major
target for aPL partly explains why pregnancy complications associated with altered
placental development and function occur in women with APS.

Apart

from

impairing

trophoblast

fusion

and

differentiation

into

giant

multinucleated cells [2], binding of aPL can decrease the production of normal
pregnancy hormone production [2, 12] and alter cytokine production [2,8]. These can
partially explain the observation of insufficient placentation (evidenced by reduced
trophoblast invasion) and limited spiral artery transformation in APS, similar to
what is seen in preeclampsia [8, 18]. Further, the process of decidualization in a
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normal pregnancy includes recruitment of specialized population of maternal
immune cells, which eventually compose about 70% of cells in the uterus during
pregnancy [19]. These cells, consisting of specialized natural killer cells (~75%), some
monocytes and dendritic cells (~15%) and regulatory T cells (~15), are not
inflammatory and do not participate in cellular cytotoxicity; rather, they play an
immunoregulatory role, which is essential for a successful pregnancy as they are
able to coexist with foreign cells and enhance maternal tolerance [19]. Unlike normal
in normal pregnancy, the decidua in APS patients has inflammatory immune cell
(macrophages and neutrophils) infiltration [20, 21, 22].

Given the propensity for vascular thrombosis in APS patients, pregnancy failure in
APS was initially attributed to thrombosis at the maternal fetal interface [3, 8]. Hence
the original method of therapy for the high rates of miscarriages was anticoagulation
with heparin with or without aspirin. To date, the standard of care for obstetrical
APS includes either low dose aspirin before conception and throughout pregnancy
up to 4 months postpartum, or low molecular weight heparin (LMWH) plus low
dose ASA during pregnancy [2]. However, both clinical observations and
experimental findings have called this basis of treatment into question. Histological
studies have shown that intravascular or intervillous blood clots are not commonly
found in samples of placentas from APS patients with miscarriage [23]. Further,
clinically, while treatment with heparin increases live birth rates, it does not prevent
late term complications of APS such as preeclampsia [3, 5, 24, 25, 26]. Moreover, its
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efficacy is controversial and is yet to be confirmed in a randomized controlled trial
[27, 28]. Hence, despite treatment, pregnant APS patients remain high-risk obstetric
cases throughout gestation. Additionally, studies have raised questions about the
safety of these therapeutics, in particular low molecular weight heparin (LMWH).
Carroll et al found that in vitro, LMWH independently up-regulated first trimester
trophoblast expression of the potent anti-angiogenic factor, soluble fms-like tyrosine
(sFlt) [29], which is associated with preeclampsia [30, 31, 32, 33, 34]. Other
researchers have reported this finding both in vitro [35, 36] and in vivo in pregnant
women treated with heparin [35, 37]. Moreover, Han et al showed that LMWH also
induced an increase in basal GRO secretion by first trimester trophoblasts [36].
These observations and findings prompted further investigation into the true
pathologic mechanism(s) involved in APS, as this would direct better the
identification of novel therapeutics and thus, the management of APS patients.

Similar to what is observed in endothelial cells, where binding of aPL to 2GPI on
the surface of the endothelial cells leads to induction of a pro-inflammatory state [1,
38], recent studies now strongly demonstrate a primary role for inflammation at the
maternal-fetal interface, rather than thrombosis, in APS-associated pregnancy
pathology. Studies have shown histological signs of acute and chronic inflammation
in the placental beds of samples of miscarriages in APS patients [21, 22].
Additionally, studies with animal models of APS have shown local and/or systemic
elevation of inflammatory markers such as TNF and tissue factor level [20, 39].
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Further, complement C3 deposition in the decidua has been observed, and blocking
of the complement pathway or tissue factor prevented aPL-mediated pregnancy
failure and associated inflammation [40, 41,42, 43]. And, as mentioned earlier, both
placentas from animal models of APS and human tissues have shown inflammatory
immune cell infiltration [20, 21]. Most recently, studies from the Abrahams lab, have
shown that aPL markedly enhances human first trimester trophoblast production of
pro-inflammatory cytokines, such as interleukin 8 (IL 8), Interleukin 1 (IL1-),
monocyte chemoattractant protein 1 (MCP-1) and GRO alpha (GRO), via
TLR4/MyD88 dependent pathway [44]. Further, the lab has illustrated that aPL
inhibit trophoblasts constitutional secretion of interleukin 6 (IL 6), is a cytokine that
is associated with trophoblast invasiveness [45, 46], leading to decreased STAT3
activity and subsequently trophoblast migration [47]. Indeed, IL-6 deficient mice
exhibit impaired implantation and reduced litter size [45, 46]. Therefore, the
trophoblast expression of IL 6 is important for normal trophoblast migration. Hence
impairment of IL-6 production by aPL, may lead to failure of the trophoblast to
effectively perform one of its basic functions in pregnancy. Also, aPL perturbs
angiogenic factor profile by up-regulating vascular endothelial growth factor
(VEGF), placental growth factor (PlGF) and soluble endoglin [29]. These findings,
combined with aforementioned in vivo animal studies, plus the dearth of thrombosis
in the histology of placenta from miscarriages in APS patients, has led to a
widespread acceptance that non-thrombotic, inflammatory mechanisms are the
main causes of defective placentation in APS. Even the observed partial efficacy of
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heparin supports this notion as studies have shown that heparin possesses antiinflammatory property due to its ability to inhibit complement activity [3, 41]. In one
study, treatment of pregnant APS mice with pure anticoagulants such as
fondaparinux and hirudin did not prevent aPL-induced pregnancy loss, whereas
treatment with unfractionated heparin and low molecular weight heparin
suppressed complement activity and increased live birth rate [41]. Hence the
observed efficacy of heparin is likely due to its anti-inflammatory properties, not its
anticoagulant property. However, heparin cannot reverse all effects of aPL on
trophoblast function and as aforementioned, might exacerbate some [29, 36]. Hence,
there continues to be growing interest towards finding alternative treatments for the
pregnant APS patients.

In the pursuit of better treatment therapy, 143-hydroxy-3-methyl-glutaryl-CoA
(HMG-CoA) reductase inhibitors (statins) have been proposed for use in preventing
APS-associated pregnancy complications. In addition to lowering cholesterol, statins
have been shown to possess anti-inflammatory properties. The anti-inflammatory
properties of statins, as observed mostly in atherogenesis, include: a decrease in
immune cell infiltration of tissues; a decrease in adhesion molecules such as ICAM1, VCAM-1, E-selectin and P-selectin; a decrease in chemoattractant proteins such as
MCP-1 and IL-8; a decrease in pro-inflammatory transcription factors such as NFB;
a decrease in pro-inflammatory enzymes such as COX-2; a decrease in proinflammatory cytokines such as TNF, IL-1, IL-6; and a decrease in inflammatory

14
serum markers such as CRP [48, 49]. Even though statins are currently
contraindicated in pregnancy due to risk of birth defects [50], the proposal for its use
in APS has been based on the finding that pravastatin can prevent fetal loss in aPLtreated mice [51]. However, the reported benefit of pravastatin in mouse model of
APS has yet to be confirmed in a human model of APS. Moreover, other studies
have reported that statins negatively affect human first trimester trophoblast by
decreasing migration and proliferation, and inducing apoptosis [52, 53, 54].
Therefore, in light of these conflicting data, we decided to test the main hypothesis
that pravastatin could prevent the effects of aPL on the trophoblast without
affecting basal trophoblast function. Thus, the objective of this current study was
to determine whether pravastatin could be used for the treatment of aPL-mediated
pregnancy complications. In order to test this, specific aims of this project were to
investigate:
Aim 1: The effects of pravastatin on human first trimester trophoblast cell viability
Aim 2: The effects of pravastatin on human first trimester trophoblast cytokine and
angiogenic factor secretion in the absence and presence of aPL.
Aim 3: The effects of pravastatin on human first trimester trophoblast cell migration
the absence and presence of aPL.
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MATERIALS AND METHODS

Source and Maintenance of Trophoblast cells
The human first trimester extravillous trophoblast cell line, HTR8, and primary
trophoblast cultures isolated from first trimester placentas (8-12wks gestation) were
used in these studies. The HTR8 cells, immortalized by SV40 [55], were a gift to the
lab from Dr. Charles Graham (Queens University, Kingston, ON, Canada).

HTR8 cells were cultured in growth media, prepared by supplementing RPMI 1640
media (from Gibco) with 10% fetal bovine serum, 0.01% of 10mM Hepes, 0.01% of
0.1mM MEM non-essential amino acids, 0.01% 1mM sodium pyruvate, and 0.01% of
100nm penicillin/streptomycin. The cells were grown at 37˚C/5% CO2 in a sterile
75cm2 polystyrene cell culture flask. When fully confluent, cells were split and then
either plated for experiments, froze in liquid nitrogen for future lab work or
maintained by continued culture.
To split confluent cells for an experiment, 3-5ml of 0.05% Trypsin was added in the
culture flask containing the cells. Trypsin was then activated by brief incubation of
the cells at 37˚C until the cells had detached. Equal volume of growth media was
added and the mixture transferred to a sterile 10ml polypropylene conical tube,
centrifuged at 21˚C at 3000rpm at room temperature for 10mins and the pellet then
re-suspended in 5-10ml of growth media. Cells were then counted and plated for
experimentation as described below.
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For primary cultures, first trimester placentas were obtained from elective
terminations of normal pregnancies performed at Yale-New Haven Hospital. The
use of patients samples was approved by Yale University's Human Investigation
Committee. Ms. Mulla prepared tissue specimens as follows: Cells were washed
with cold Hanks Balanced Salt Solution to remove excess blood. They were then
scraped from the membranes, transferred to trypsin-EDTA digestion buffer and
incubated at 37˚C for 40 minutes with shaking. The mixture was then passed
through a nylon strainer and then layered over Lymphocyte Separation Media and
centrifuged at 2000rpm for 25 minutes. The cellular interface containing the
trophoblast cells was collected and re-suspended in D-MEM with D-valine
supplemented with 10% normal human serum and cultured in 5% CO2 at 37˚C.

Antiphospholipid antibodies
The mouse IgG1 anti-human 2GPI monoclonal Ab (mAb), IIC5, was used in these
studies. This antibody was produced by Larry W. Chamley (department of
Obstetrics and Gynecology, University of Auckland, New Zealand), under sterile
conditions, and was filter-sterilized prior to use. IIC5 was cloned from mice
immunized with purified human 2GPI, and has been previously characterized [56].
Like human aPL, IIC5 binds 2GPI, but only when it is immobilized on a suitable
negatively charged surface, such the phospholipids, cardiolipin, phosphatidyl
serine, or irradiated polystyrene [57]. IIC5 binds to first trimester trophoblast cells
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and similar to patient-derived polyclonal aPL, it alters trophoblast function by
inducing pro-inflammatory cytokine expression and perturbing angiogenic factor
balance [29, 44].

Cell viability studies
Trophoblast cell viability was determined using the CellTiter 96 viability assay. Cells
were plated in wells of a 96-well plate at 1x104 cells per well in growth media, at
total volume of 100L, and cultured at 5% CO2 and 37˚C.When cells became 70%
conﬂuent media was replaced with 50L of serum-free Opti-MEM media
(Invitrogen), and cultured for another 4hrs. Treatments were prepared at double the
target concentrations and 50L of treatments were added to the wells, bringing
down the treatments to the final concentrations of CPT at 4M and pravastatin at
0.1, 1, 2.5 and 5g/ml. All treatments were prepared in Opti-MEM. Cells were then
incubated for 72hrs at 37˚C and afterwards, 20L CellTiter 96TM substrate was added
to all wells. Cells were the incubated for an additional 2hrs at 37°C and optical
densities were read at 490 nm. All samples were assayed in triplicate, and cell
viability was presented as a percentage of the untreated control.

Cytokine and angiogenic factor secretion studies
Cytokine and angiogenic factor secretion were assessed using enzyme linked
immunosorbent assay (ELISA) and multiplex analysis. Prior to this, HTR8
trophoblast cells were plated at 6 x 104cells/ml in total volume of 2ml of growth
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media, in sterile 35mm petri dishes and cultured in growth media in similar
conditions as above. When the cells were 70% confluent, the growth media was
replaced with 2ml of OptiMEM and cells incubated for 4hrs at 37°C. OptiMEM was
then replaced with treatments that consisted of IIC5 (aPL) at 20g/ml (in OptiMEM)
in the presence and absence of pravastatin at either 0.5 or 2.5g /ml in OptiMEM.
After 72 hours at 37°C, cell-free supernatants were collected by centrifugation at
2000rpm at 4C for 5 minutes and stored at -80˚C until analysis was performed.

For primary human first trimester trophoblast, the cells had heterogeneous growth
rates since they were collected from different patient samples. As such, when plated,
the cells in different plates attained 70% and 100% confluence at different times.
Additionally, since we cannot culture them as long as the immortalized cell lines, we
performed the experiments as soon as some of the petri dishes had 70% confluent
cells. Therefore following treatments, just as in the case of HTR8 cells, and collection
of supernatants, the cells were lysed and the total proteins collected. Bicinconinic
assay (BCA) analysis was done to normalize the protein levels in the different
treatment groups and to appropriately interpret the ELISA results. Total protein,
was collected thus: After collecting the supernatant cold 1xPBS was added to the
dishes and cells scraped off the dish using an autoclaved cell scraper. The mixture
was then transferred to 15ml conical tube and centrifuged at 1500rpm for 10mins at
4C. The pellet was re-suspended with 50L of lysis buffer (containing 0.02% PIC
and PMSF), vortexed and incubated on ice for 20mins. Afterwards, the lysate was
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centrifuged at 13000rpm for 15mins at 4C and supernatant stored at -40C until
ready for BCA assay.
At the time of analysis of supernatants from either HTR8 cells or primary
trophoblasts, supernatants were thawed at room temperature and evaluated the
concentrations of interleukin 8 (IL-8), vascular endothelial growth factor (VEGF),
placenta growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble
Endoglin (sEndoglin) using R&D systems ELISA kits and following the
manufacturer’s instructions. The levels of IL-8, IL-1, GRO- and VEGF were also
determined by multiplex analysis of the supernatants using the BioPLex assay with
detection and analysis using the Luminex 100 IS system.

Cell migration studies
To assess trophoblast migration, a two chamber colorimetric assay was employed.
The top chambers were made of 8µm pore size cell culture inserts, while the lower
chambers were 24-well tissue culture plates. The lower chamber was filled with
800µL of OPtiMEM and the top chamber was seeded with 1x105cells HTR8 cells,
which were suspended in 200µL of treatments (media alone, aPL, pravastatin, or
both). Following a 48hr incubation, inserts were removed and trophoblast migration
across the membrane was determined using the QCM 24-Well Colorimetric Cell
Migration assay according to the manufacturer’s direction (Chemicon International).
Brieﬂy, the filters on the top chamber was removed and transferred into wells
containing 250l of cell stain. This process stains the migrated cells, which were
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trapped in the pores of the filter, to stain. Afterwards, excess stain was removed by
dipping the bottom of the filter into a beaker of distilled water and transferring filter
into a clean well.

of extraction buffer was then added to the wells and cells left

to gently rock at 1.5rpm at room temperature for 15mins.

of the resulting

colored mixture was transferred to a 96-well plate and optical densities read in
triplicate at 560 nm. A 100% migration control consisted of 1 x 105 HTR8 cells placed
directly in the 24-well plate without any insert. Observed optical density values
were measured using a BioRad plate reader, and were compared to the 100%
migration control to determine the relative percent migration.

Statistics
All experiments were performed at least three times. I produced all of the data
involving the HTR8 cell lines (cell viability, cytokine and angiogenic factor studies,
and migration studies) as well as two sets of data for primary trophoblasts cell
viability studies and one set of data for IL-8 levels. Ms. Mulla obtained the
remaining data for primary trophoblast viability studies, cytokine and angiogenic
factor production in the presence of pravastatin. Similarly, with the help of Dr.
Abrahams, I performed the statistical analysis for data for HTR8 cells while Dr.
Abrahams performed the statistical analysis of data for the primary trophoblast
cells. Data are expressed as mean ± standard deviation (S.D.) of pooled experiments.
Statistical signiﬁcance (p<0.05) was determined using either the one-way Anova
with the Bonferroni correction, or the paired student’s t-test.

21
RESULTS

Effects of pravastatin trophoblast viability
Previous studies have reported that statins can prevent human trophoblast
proliferation and induce trophoblast apoptosis [52]. Therefore, the first objective of
this study was to determine the effects of pravastatin on trophoblast cell viability
under our laboratory conditions. Thus, the HTR8 cell line and primary trophoblast
cultures were treated for 72hrs with either no treatment (NT), camptothecin (CPT,
4M), which serves as a positive control for cell death, or pravastatin at 0.1, 1, 2.5 or
5 g/ml. As shown in Figure 1A, treatment with pravastatin at the highest dose of
5g/ml significantly decreased the viability of the first trimester trophoblast cell
line, HRT8, by 22.9 ± 33.1% (p<0.05). As expected our positive control, CPT, also
significantly decreased HTR8 cell viability by 78%  4.8% (p<0.001). At the lower
doses of pravastatin (0.1 – 2.5g/ml), there was no significant effect on HTR8
trophoblast cell viability (Figure 1A). In contrast, pravastatin, at all doses, did not
have any affect on the viability of primary human first trimester trophoblast cell
(Figure 1B).
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Figure 1: Effects of pravastatin on viability of human first trimester trophoblast cells after
incubation for 72hrs. (A) HTR8 trophoblast cell line (B) primary human first trimester
trophoblasts. *P<0.05; **P<0.001; NT = no treatment, CPT = 4M of camptothecin.

Due to the effect of the high dose pravastatin on HRT8 cells, all subsequent
experiments were performed at lower doses that did not affect cell viability. Thus,
for all other experiments, a low dose of 0.5g/ml and a high dose of 2.5g/ml was
used.

Effects of Pravastatin on aPL-induced inflammation on trophoblasts.
We have previously demonstrated that the mouse anti-human 2GPI mAb, IIC5, and
patient-derived polyclonal aPL, with 2GPI activity, induce a human first trimester
trophoblast inflammatory response by up-regulating the cell’s secretion of IL-8, IL1 and GRO- [36, 44].

Therefore, we investigated whether pravastatin could

counter these effects of aPL. Thus HTR8 cells were treated for 72hrs with or without
the anti-2GPI Ab, in the presence of either media, pravastatin at 0.5g/ml or
pravastatin at 2.5g/ml after which IL-8, IL-1 and GRO- secretion was measured.
As shown in figure 2A high and low doses of pravastatin had no significant effect on
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basal IL-8 or GRO- secretion by HTR8 cell lines, but did significantly elevate basal
IL-1 at the high dose (NT groups in figure 2A). Surprisingly, the presence of
pravastatin at both high and low doses significantly augmented the anti-2GPI mAbinduced up-regulation of IL-8 secretion by HTR8 cells (anti-2GPI mAb groups in
figure 2A). Additionally, low dose pravastatin significantly augmented the anti2GPI mAb up-regulation of IL-1

atin had no significant effect

on the up-regulation of GRO- induced by the anti-2GPI mAb on HTR8 cells.

Figure 2A: Pravastatin augments aPL-mediated secretion of IL-8, IL-1, and GRO by human first
trimester trophoblast cell line, HTR8. Treatment groups received 20g/ml of anti-2GP1 mouse Ab (IIC5)
and 0.5 or 2.5g/ml of pravastatin and all (including control) were incubated for 72hrs. NT = No
treatment; *P<0.05; **P< 0.01; a = P<0.05 relative to NT; b = P<0.01 relative to NT.
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In order to validate our findings, we next tested whether pravastatin had similar
effects on primary human first trimester trophoblasts. Interestingly, in contrast to
our findings using the HTR8 cell line, neither high nor low dose pravastatin altered
the basal cytokine production in primary human first trimester trophoblasts (figure
2B). Also, pravastatin had no effect on the aPL-induced up-regulation of proinflammatory cytokines, IL-8, IL-1 and GRO-, secreted by primary trophoblast
cells (figure 2B).

Figure 2B: Effects of pravastatin on aPL -mediated secretion of IL-8, IL-1, and GRO by
primary human first trimester trophoblast. Treatment groups received 20g/ml of anti2GP1 mouse Ab (IIC5) and 0.5 or 2.5g/ml of pravastatin and all (including control) were
incubated for 72hrs. NT = No treatment; *P<0.05 and **P< 0.01 relative to NT.
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Effects of pravastatin on aPL-induced anti-angiogenic factor response in
trophoblasts.
We have recently demonstrated that the mouse anti-2GPI mAb, IIC5, and patientderived polyclonal aPL, alter angiogenic factor profile by up-regulating human first
trimester trophoblast cell secretion of VEGF, PlGF and soluble endoglin [29, 36].
Therefore, one of the objectives of this study was to determine whether pravastatin
impacts these angiogenic factor alterations caused by aPL. To test this, HTR8 cells
were treated for 72hrs with or without the anti-2GPI Ab, in the presence of either
media, pravastatin at 0.5g/ml or pravastatin at 2.5g/ml after which VEGF, PlGF,
soluble endoglin and sFlt-1 levels were measured. As shown in figure 3A,
pravastatin alone had no effect on the basal production of VEGF, PlGF or sEndoglin
by HTR8 cells (NT groups in Figure 3A). But, at the high dose of 2.5g/ml, basal
sFlt-1 secretion was significantly increased (p <0.01). Consistent with our prior
studies, treatment of HTR8 cells with anti-2GPI mAb led to up-regulation of VEGF,
PlGF and soluble endoglin with down-regulation of sFlt-1. Pravastatin slightly, yet
significantly, reduced the ability of the anti-2GPI mAb to increase HTR8 VEGF and
PlGF secretion (anti-2GPI mAb groups in Figure 3A). However at both high and
low doses, pravastatin significantly augmented anti-2GPI mAb-induced upregulation of sEndoglin secretion by HTR8 (p< 0.01 and p<0.05 respectively).

Since we had observed differential effects of pravastatin on basal and aPL-mediated
changes in pro-inflammatory cytokine secretion by HTR8 cells and primary
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trophoblasts, we were curious about the effects of pravastatin on basal and aPLmediated changes in aniogenic factor secretion by primary human first trimester
trophoblasts. Apart from a significant decrease in basal sEndoglin level, pravastatin
did not alter basal angiogenic factor production by primary first trimester
trophoblasts. Furthermore, similar to the pattern in pro-inflammatory cytokine
production, pravastatin did not reverse any of the aPL-mediated changes in
angiogenic factor profiles of primary human first trimester trophoblasts (figure 3B).
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Figure 3A: Pravastatin augments aPL-induced up-regulation of soluble endoglin (sEndo) by human
first trimester trophoblast cell lines, HTR8. Treatment groups received 20g/ml of anti-2GP1 mouse
Ab (IIC5) and 0.5 or 2.5g/ml of pravastatin and all (including control) were incubated for 72hrs. NT
= No treatment; *P<0.05; **P< 0.01; a = P<0.05 relative to NT; b = P<0.01 relative to NT.
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Figure 3B: Figure 2B: Effects of pravastatin on aPL-mediated secretion of angiogenic factors by
primary human first trimester trophoblast. Treatment groups received 20g/ml of anti-2GP1
mouse Ab (IIC5) and 0.5 or 2.5g/ml of pravastatin and all (including control) were incubated for
72hrs. NT = No treatment; *P<0.05 and **P< 0.01 relative to NT.

Pravastatin does not reverse aPL inhibition of trophoblast migration.
In addition to inducing a pro-inflammatory and anti-angiogenic profile, anti-2GPI
mAb limit first trimester trophoblast migration [47]. Since the ability to migrate is
one of the essential functions of the trophoblast and impaired migration and
invasion predisposes to fetal loss in APS, it was important to us to assess whether
pravastatin could mitigate this impaired migration caused by aPL. Therefore, HTR8
cells were treated for 48hrs with or without the anti-2GPI Ab, in the presence of
either media, pravastatin at 0.5g/ml or pravastatin at 2.5g/ml after which cell
migration was determined using colorimetric two-chamber migration assay. As
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shown in Figure 4, pravastatin alone at the low dose of 0.5g/ml slightly but
significantly reduced basal HTR8 cell migration (p < 0.01). At either doses,
pravastatin had no effect on the inhibition of trophoblast migration induced by the
anti-2GPI mAb.

Figure 4: Pravastatin did not reverse aPL-antibody mediated decrease in migration of human first
trimester trophoblast cell line, HTR8. Treatment groups received 20g/ml of anti-2GP1 mouse Ab
(IIC5) and 0.5 or 2.5g/ml of pravastatin and all (including control) were incubated for 72hrs. NT =
No treatment; *P<0.05; **P< 0.01; a = P<0.05 relative to NT; b = P<0.01 relative to NT.
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DISCUSSION

The majority (about 90%) of fetal losses seen in APS patients occurs during the first
trimester, usually before 14 weeks of gestation [5]. Since aPL are present at the time
of implantation, this suggests that the pathology in obstetric APS may evolve during
the first trimester of pregnancy, similar to what is thought for preeclampsia [58, 59].
Therefore, understanding this pathology as it occurs early in pregnancy would help
in the prevention of both the fetal loss and later term complications in APS. For this
reason, we have chosen to study APS pathology and the efficacy of novel
therapeutics in vitro using first trimester trophoblast cells.

While women with APS are routinely treated with LMWH during pregnancy,
clinical and experimental studies have highlighted the potential lack of efficacy of
this regimen, as well as potential problems resulting from the treatment [27, 28, 29,
35, 36, 37]. Consequently, there is a need for alternative preventative strategies in the
management of pregnant women with APS. Recent studies in mice have
demonstrated that the statin, pravastatin, prevents the onset of symptoms of
preeclampsia brought about either by the overexpression of the anti-angiogenic
factor human sFlt-1 [32, 33, 34] or the genetic background [60, 61], suggesting that it
could be beneficial in prevention of preeclampsia.
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Preeclampsia is a common adverse pregnancy outcome in women with APS [6, 62,
63]. In this patient population, it can have early-onset and particularly be severe
leading to high rate of preterm delivery [62]. Furthermore, similar to what is seen in
preeclampsia, the histology of the placenta in APS shows shallow invasion of the
decidua by the trophoblast, as well as poor remodeling of maternal spiral arteries
[16, 23]. However, the mechanism for this observed phenomenon is likely different
from preeclampsia. In APS, there is premature stimulation of cytotrophoblast
proliferation and syncytial fusion leading to depletion of cytotrophoblasts [16].
Since the cytotrophoblast is the trophoblastic stem cell, there is ultimately reduced
number of stem cell pool to form syncytiotrophoblasts (the most important
component of materno-fetal barrier) and extravillous trophoblasts that invade the
decidua and maternal vessels. There is no consensus on the cause of the premature
stimulation of cytotrophoblast proliferation but with the large body of literature
showing inflammation in APS, inflammation could play a role in this observed
phenomenon. Due to the similar end results in placental morphology, the
association between preeclampsia and APS, and the noted anti-inflammatory
properties statins, researchers have tested the efficacy of pravastatin in APS model.
Pravastatin was shown to prevent aPL-mediated pregnancy loss in mice [51, 64].
These findings of the effects of pravastatin in mouse models of classical
preeclampsia and APS have led to an interest in the use of statins to treat pregnancy
complications, such as preeclampsia and those associated with APS [51, 64]. Indeed,
a randomized placebo-controlled clinical trial on statins for the prevention of early-
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onset preeclampsia, Statins to Ameliorate Early Onset Pre-eclampsia (StAmP Trial),
is currently underway [65]. Since the impact of statins have yet to be tested in a
human model of aPL-associated pregnancy problems, and studies using normal
human placental explants have raised concerns over the use of statins during
pregnancy [52, 53, 54], we sought to determine whether statin could prevent aPLmediated effects using a human trophoblast in vitro system.

We used pravastatin in our studies because it is the statin that has been shown to be
least associated with risk of fetal anomaly due to low lipophilicity [66]; since it does
not easily crossing the placenta, it is thought to remain on the maternal side of the
placenta. Since the objective of this study was to find out whether pravastatin could
be used for the treatment of aPL-mediated pregnancy complications, low diffusion
through the placenta was an important feature as any favorable finding can be
extrapolated to an in vivo human model without fear of damage to the fetus, while
still potentially benefiting placentation by minimizing the inflammation at the
maternal side of the placenta and countering the effects of aPL on the placenta. In
addition to having low permeability through the placenta, pravastatin was used
because it has been shown to have beneficial effects in previous experimental studies
in mice [32, 33, 34, 51]. Based on prior studies using pravastatin [54] and other
statins [52], we were able to select a dose range that we considered appropriate to
address the question in this study. In our preliminary experiments we found that
while pravastatin had no adverse effect on the viability of primary first trimester
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trophoblast cultures, pravastatin at 5g/ml, reduced the viability of human first
trimester trophoblast cell line HTR8, an observation also made by other groups
using human first trimester placental explants [52, 54]. Hence, we used pravastatin
at concentrations (0.5g/ml and 2.5g/ml) that did not induce cell death. At these
lower doses, we found that pravastatin modestly enhanced sFlt-1 and IL-1
secretion and reduced the migratory capacity of HTR8 trophoblast. Our findings are
in keeping with the observation by others, demonstrating that statins reduce
trophoblast cell migration and outgrowth from first trimester explant cultures [52,
53].

We also failed to observe unequivocal beneficial effects of pravastatin on HTR8
trophoblast exposed to the anti-2GPI mAb. Pravastatin was unable to prevent the
up-regulation of the pro-inflammatory cytokines IL-8, IL-1, and GRO-; the
induction of sEndoglin; or the reduction in cell migration upon exposure to aPL
antibody. Pravastatin did, however, reduce aPL antibody-induced VEGF and PlGF
secretion. While this reached significance, these effects were modest and unlikely to
have physiological consequences. Moreover, this finding does not support the
observation in the mouse model of preeclampsia where pravastatin increases PlGF
expression [34].

Where we did see a marked effect by pravastatin was in its ability to augment aPLinduced secretion of IL-8, IL-1 and sEndoglin by the HTR8 trophoblast cell line.
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Indeed studies using immune cells have shown that statins can enhance LPSinduced inflammation, including IL-8 and IL-1 production [67, 68, 69]. Since aPLinduced IL-8 and IL-1 is mediated by TLR4 [44], the mechanism by which
pravastatin enhances the trophoblast inflammatory response to aPL may be similar.
However, when the effect of pravastatin was tested using primary human first
trimester trophoblast cultures, we found no positive or negative effects on either
basal or aPL-stimulated cytokine and angiogenic factor production.

The reason for the difference in observations between the trophoblast cell line and
primary cells may be because the primary cultures are a more heterogeneous
population. Alternatively, since we have observed similar effects of the aPL on both
the primary trophoblast and the trophoblast cell line in our previous studies [29, 44],
our results may indicate that pravastatin has differential effects on the two types of
culture. Indeed, the augmentation of aPL-induced IL-1, IL-8 and sEndoglin
secretion by pravastatin in the cell line may be a reflection of pravastatin's ability to
slightly elevate the cell line's basal production of these factors; an observation not
seen in the primary cultures.

Based on our observations we can conclude that while pravastatin may not be
overtly detrimental to the trophoblast in the absence of aPL in terms of cytokine and
angiogenic factor production, alone it still might impair placental cell function by
limiting migration, which is critical for normal placentation; and it fails to protect
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the trophoblast from aPL effects. Thus, our findings might be taken to not support
the use of pravastatin in APS patients. Why this is in contrast to the in vivo studies
showing that pravastatin prevents aPL-induced pregnancy loss may simply be a
consequence of species differences, with different pharmacokinetics in each species.
Alternatively, it might be a result of methodology. In vivo, significant maternal
blood flow to the villous tissues begins around weeks 10-12; before this, there is low
oxygen concentration in the intervillous space and it enables trophoblast to rapidly
proliferate while protected from free oxygen free radical [16].

This hypoxic

condition is not represented in our experimental system as we performed our
incubations at normoxic conditions. Therefore, another possibility for the differences
between the cell types could be a result of the oxygen concentration used.
Furthermore, in the mouse model of aPL-induced pregnancy failure, pravastatin
was administered prior to aPL exposure, whereas in our in vitro model, trophoblast
cells were treated simultaneously with aPL and pravastatin. Moreover, the mouse
model explains the pathogenesis of APS-associated pregnancy failure and the
success of pravastatin in preventing this is based on its ability to prevent aPLinduced neutrophil tissue factor and PAR-2 expression [51, 64], rather than the direct
effects of aPL on the trophoblast, as in our model [29, 36, 44, 47]. So in our system,
which is relatively free of those agents, we observed a differential effect. Thus, we
can conclude that in our study, pravastatin fails to prevent the direct effect of aPL on
the placenta and trophoblast function.
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Finally, our findings demonstrate that, in vitro, pravastatin does not prevent the
effects of anti-2GPI Abs on human first trimester trophoblast cell function and,
therefore, may not be beneficial as a therapeutic for pregnant APS patients. Though
there is a study in the mouse model of APS showing reduced miscarriage rates due
to pravastatin treatment, whether pravastatin can prevent aPL-associated late-term
pregnancy complications is unclear at this time because this efficacy is yet to be
reproduced in other studies; and prior to our study, there was no study testing
pravastatin in human APS model. Additionally, though the litters produced in the
mouse model after treatment with pravastatin appeared normal, we do not yet
know the long-term effects of this treatment on the off-spring. So more studies are
needed to address these issues and determine the effectiveness of pravastatin in the
prevention of aPL-associated pregnancy complications in humans. In the current
state of care of APS patients, there is use of heparin and/or aspirin, which while
they do not prevent late term complications, they are non-teratogens and to some
extent do significantly reduce miscarriages. So while current research aims to
improve treatment options in APS, at this point the risk of using pravastatin, a
potential teratogen, outweighs its benefit in APS. In contrast to APS, there is more
data that can be viewed as support of the benefit of pravastatin in models of
preeclampsia. However, while there is abnormal placentation in both classical
preeclampsia and APS, it is worth noting that both are separate entities with
different underlying mechanisms; therefore efficacy of pravastatin in classical
preeclampsia may not directly translate into efficacy for preeclamptic APS patients.
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In summary, this research study has demonstrated that pravastatin augments the
aPL-induced inflammation and anti-angiogenic profile in the first trimester
trophoblast cell line, but has no effect on aPL-induced responses in primary
trophoblast cells. These findings demonstrate that pravastatin does not prevent the
effects of aPL antibody on first trimester trophoblast cell function, and so may not be
beneficial as a therapeutic for pregnant APS patients. However, with respect to the
normal functions of the primary human first trimester trophoblast cell, particularly
their innate ability to migrate, produce cytokines necessary for its function (such as
IL 6), and produce angiogenic factors under resting, basal conditions, our study did
not reveal any overt negative effects of pravastatin. With this finding and the fact
that certain studies have illustrated its benefits in preeclampsia, independent of aPL
[32, 33, 34], one might argue that pravastatin might be considered for use in nonAPS patients at high risk for preeclampsia. While studies suggest that this could be a
beneficial option in preeclampsia, the risk of fetal anomaly with statin use still
remains a significant possible adverse outcome. Therefore, since delivery of the
placenta is a definitive treatment for preeclampsia, and in many cases can be
accomplished without dangers of the lifetime sequel of prematurity, it may be
worthwhile to follow that route for mild to moderate preeclampsia. Pravastatin use
can then be reserved for the few cases of severe preeclampsia where the fetus is
significantly premature and delivery would place the fetus at high risk of lifetime
complications of prematurity. Further, even in such cases, it is difficult to
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extrapolate, from our study, the appropriate dose that would be required for
treatment of preeclampsia since the only documented use of statins in pregnancy is
old literature about inadvertent use for treatment of hyperlipidemia. Also, unlike in
our studies, statins are typically clinically dosed on a fixed milligram amount
regardless of patient weight. Additionally though not well studied at this point, the
physiology of pregnancy could alter the pharmacokinetics of pravastatin and such
changes may not be fully captured in in vitro studies like ours. Therefore more
studies, such as the on-going randomized controlled clinical trial [65] would provide
such helpful information. Meanwhile, there are limited in vivo studies using
pravastatin to prevent aPL-mediated pregnancy complications and so more research
is needed in that area. Future studies by us will be directed towards elucidating the
mechanism through which pravastatin augments aPL-mediated responses in the cell
line.

39
REFERENCES
1. Durrani OM, Gordon C, and Murray PI. Primary Anti-phospholipid antibody
syndrome (APS): Current concepts. Surv Ophthalmol 2002; 47: 215-238.

2. Galarza-Maldonaldo C, Kourilovitch MR, Perez-Fernandez OM, Gaybor M,
Cordero C, et al. Obstetric antiphospholipid syndrome. Autoimmune Reviews
2011; 288-295.

3. Hoppe B, Burmester G, and Dorner T. Heparin or aspirin or both in the
treatment of recurrent abortions in women with antiphospholipid antibody
(syndrome). Curr Opinion in Rheum 2011; 23: 299-304.

4. Meroni PL, Raschi E, Grossi C, Pregnolato F, Trepidi L, et al. Obstetric and
vascular APS: Same autoantibodies but different diseases? Lupus 2012; 21:
708-710.

5. Rai R, Cohen H, Dave M. and Regan L. Randomised control trial of aspirin
and aspirin plus heparin in pregnant women with recurrent miscarriage
associated with phospholipid antibodies (or antiphospholipid antibodies).
BMJ 1997; 253-257.

40
6. Biggioggero

M,

and

Meroni

PL.

The

geoepidermiology

of

the

antiphospholipid antibody syndrome. Autoimmunity Reviews 2010; 9: A299A304.

7. Lim W, and Crowther MA. Antiphospholipid antibodies: a critical review of
the literature. Curr Opin Hematol 2007; 14: 494-499.

8. Abrahams VM. Mechanisms of antiphospholipid antibody-associated
pregnancy complications. Thrombosis Research 2009; 124: 521-525

9. Gill JM, Quisel AM, Rocca PV, and Walters DT. Diagnosis of systemic lupus
erythematosus. Am Fam Physician 2003; 68: 2179-1286.

10. Fadeel B, and Xue D. The ins and outs of phospholipid asymmetry in the
plasma membrane: roles in health and disease. Crit Rev Biochem Mol Biol.
2009; 44 (5): 264-277.

11. Demchenko AP. The change of cellular membranes on apoptosis:
fluorescence detection. Exp Oncol 2012; 34(3): 263-268.

41
12. Rote NS, Vogt E, DeVere G, Obringer AR, and Ng AK. The role of placental
trophoblast in the pathophysiology of the antiphospholipid antibody
syndrome. American Journal of Reproductive Immunology 1998; 39: 125-136.

13. Rote NS, Chang J, Katsuragawa H, Ng AK, Lyden TW, et al. Expression of
phosphatidylserine-dependent antigens on the surface of differentiating
BeWo human choriocarcinoma cells. American Journal of Reproductive
Immunology 1995; 33(1): 114-121.

14. Lyden TW, Vogt E, Ng AK, Johnson PM, and Rote NS. Monoclonal
antiphospholipid antibody reactivity against human placental trophoblast.
American Journal of Reproductive Immunology 1992; 22(1): 1-14.

15. Lyden TW, Ng AK, and Rote NS. Modulation of phosphatidylserine epitope
expression by BeWo cells during forskolin treatment. Placenta 1993; 14: 177186.

16. Bose P, Kadyrov M, Goldin R, Hahn S, Backos M, et al. Abberations of early
trophoblast differentiation predispose to pregnancy failure: lessons from the
anti-phospholipid syndrome. Placenta 2006; 27: 869-875.

42
17. Adler RR, Ng AK, and Rote NS. Monoclonal antiphosphatidylserine antibody
inhibits intercellular fusion of the choriocarcinoma line, JAR. Biology of
Reproduction 1995; 53: 905-910.

18. Han AR, Ahn H, Vu P, Park JC, Gilman-Sachs A, et al. Obstetrical outcome of
anti-inflammatory and anticoagulant therapy in women with recurrent
pregnancy loss or unexplained infertility. American Journal of Reproductive
Immunology 2012; 68: 418-427.

19. Red-Horse K, Drake PM, and Fisher SJ. Human pregnancy: the role of
chemokine networks at the fetal-maternal interface. Expert reviews in molecular
medicine 2004; 6(11): 1-14.

20. Redecha P, Tilley R, Tencati M, Salmon JE, Kirchhofer D, et al. Tissue factor: a
link between C5a and neutrophil activation in antiphospholipid antibody
induced fetal injury. Blood 2007; 110: 2423–2431.

21. Stone S, Pijnenborg R, Vercruysse L, Poston R, Khamashta MA, et al. The
placental bed in pregnancies complicated by primary antiphospholipid
syndrome. Placenta 2006; 27: 457–67.

43
22. Van Horn JT, Craven C, Ward K, Branch DW and Silver RM. Histological
features of placentas and abortion specimens from women with
antiphospholipid and antiphospholipid-like syndrome. Placenta 2004; 25: 642648.

23. Sebire NJ, Fox H, Backos M, Rai R, Paterson C, et al. Defective endovascular
trophoblast invasion in primary antiphospholipid antibody syndromeassociated early pregnancy failure. Human Reproduction 2002; 17(4): 1067-1071.

24. Backos M, Rai R, Baxter N, Chilcott IT, and Cohen H. Pregnancy
complications in women with recurrent miscarriage associated with
antiphospholipid antibodies treated with low dose aspirin and heparin. Br J
Obstet Gynaecol 1999; 106: 102-107.

25. Zaikas PD, Pavlou M, and Voulgarelis M. Heparin treatment in
antiphospholipid syndrome with recurrent pregnancy loss: a systematic
review and meta-analysis. Obstet Gynecol 2010; 115(6): 1256-1262.

26. Levy RA, Jesus GRR and Jesus NR. Obstetric antiphospholipid syndrome:
still a challenge. Lupus 2010; 19: 457-459.

44
27. Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, et al. Low
molecular weight heparin and aspirin for recurrent pregnancy loss: Results
from randomized, controlled HepASA trial. J. Rheumatol 2009; 36: 279-287.

28. Farquharson RG, Quenby S and Greaves M. Antiphospholipid syndrome in
pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002;
100: 408-413.

29. Carroll TY, Mulla MJ, Han CS, Brosens JJ, Chamley LW, et al. Modulation of
trophoblast angiogenic factor secretion by antiphospholipid antibodies is not
reversed by heparin. Am J Reprod Immunol 2011; 66(4): 286–296.

30. Gu Y, Lewis DF, and Wang Y. Placental productions and expressions of
soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental
growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol
Metab 2008; 93: 260–266.

31. Maynard SE, Min JY, Merchan J, Lim KH, Li J, et al. Excess placental soluble
fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial
dysfunction,hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;
111: 649–658.

45
32. Constantine MM, Tamayo E, Lu F, Bytautiene E, Longo M, et al. Using
pravastatin to improve the vascular reactivity in a mouse model of soluble
fms-like tyrosine kinase-1-induced preeclampsia. Obstet Gynecol 2012; 116:
114-120.

33. Fox KA, Longo M, Tamayo E, Kechichian T, Bytautiene E, et al. Effects of
pravastatin on mediators of vascular function in a mouse model of soluble
Fms-like tyrosine kinase-1-induced preeclampsia. Am J Obstet Gynecol 2011;
205(366): e361-365.

34. Kumasawa K, Ikawa M, Kidoya H, Hasuwa H, Saito-Fujita T, et al.
Pravastatin induces placental growth factor (PGF) and ameliorates
preeclampsia in a mouse model. Proc Natl Acad Sci U S A 2011; 108: 1451-1455.

35. Sela S, Natanson-Yaron S, Zcharia E, Vlodavsky I, Yagel S, and Keshet E.
Local retention versus systemic release of soluble VEGF Receptor-1 are
mediated by heparin-binding and regulated by heparanase. Circ Res. 2011;
108: 1063-1070.

36. Han CS, Mulla MJ, Bronsens JJ, Chamley LW, Paidas MJ, et al. Aspirin and
heparin effect on basal and antiphospholipid antibody modulation of
trophoblast function. Obstet Gynecol. 2011; 118(5): 1021-1028.

46

37. Rosenberg VA, Buhimschi IA, Lockwood CJ, Paidas MJ, Dulay AT, et al.
Heparin

elevated

circulating

soluble

fms-like

tyrosine

kinase-1

immunoreactivity in pregnant women receiving anticoagulation therapy.
Circulation 2011; 124: 2543-2553.

38. Meroni PL, Borghi MO, Raschi E, and Tedesco F. Pathogenesis of
antiphospholipid syndrome: understanding the antibodies. Nat. Rev.
Rheumatology 2011; 7: 330-339.

39. Berman J, Girardi G, and Salmon JE. TNF-alpha is a critical effector and a
target for therapy in antiphospholipid antibody-induced pregnancy loss. J
Immunol 2005; 174: 485–90.

40. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, et al. Complement
C5a receptors and neutrophils mediate fetal injury in the antiphospholipid
syndrome. J Clin Invest 2003; 112: 1644–54.

41. Girardi G, Redecha P, and Salmon JE. Heparin prevents antiphospholipid
antibody induced fetal loss by inhibiting complement activation. Nat Med
2004; 10: 1222–1226.

47
42. Shamonki JM, Salmon JE, Hyjek E, and Baergen RN. Excessive complement
activation is associated with placental injury in patients with
antiphospholipid antibodies. Am J Obstet Gynecol 2007; 196(167): e1–5.

43. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, et al. Complement C3
activation is required for antiphospholipid antibody-induced fetal loss. J Exp
Med 2002; 195:211–220.

44. Mulla MJ, Brosens JJ, Chamley LW, Giles I, Pericleeous C, et al.
Antiphospholipid antibodies induce a proinflammatory response in first
trimester trophoblast via the TLR4/MyD88 pathway. Am J Reprod Immunol
2009; 62: 96-111.

45. Fitzgerald JS, Poehlmann TG, Schleussner E, and Markert UR. Trophoblast
invasion: the role of intercellular cytokine signaling via signal transducer and
activator of transcription 3 (STAT3). Human Reproduction Update 2008; 14(4):
335-344.

46. Dominguez F, Martinez S, Quinonero A, Loro F, Horcajadas JA et al. CXCL10
and IL-6 induce chemotaxis in human Trophoblast cell lines. Molecular Human
Reproduction 2008; 14(7): 423-430.

48
47. Mulla MJ, Myrtolli K, Brosens JJ, Chamley LW, Paidas MJ, et al.
Antiphospholipid antibodies limit trophoblast migration by reducing IL-6
production and STAT3 activity. Am J Reprod Immunol 2010; 63 (5): 339-348.

48. Blanco-Colio LM, Tunon J, Martin-Ventura JL, and Egido J. Antiinflammatory
and immunomodulatory effects of statins. Kidney International 2003; 63: 12-23.

49. Antonopoulos AS, Margaritis M, Lee R, Channon K, and Antoniades C.
Statins as
Anti-inflammatory agents in atherogenesis: Molecular mechanisms and
lessons from the recent clinical trials. Current Pharmaceutical Design 2012; 18:
1519-1530.

50. Edison RJ and Muenke M. Mechanistic and epidemiologic considerations in
the evaluation of adverse birth outcomes following gestational exposure to
statins. American Journal of Medical Genetics 2004; 131A: 287-298.

51. Girardi G. Pravastatin prevents miscarriages in antiphospholipid antibodytreated mice. J Reprod Immunol 2009; 82: 126-131.

49
52. Kenis I, Tartakover-Matalon S, Cherepnin N, Drucker L, Fishman A, et al.
Simvastatin has deleterious effects on human first trimester placental
explants. Human Reprod 2005; 20: 2866-2872.

53. Tartakover-Matalon S, Cherepnin N, Kuchuk M, Drucker L, Kenis I et al.
Impaired migration of trophoblast cells caused by simvastatin is associated
with decreased membrane IGF-1 receptor, MMP2 activity and HSP27
expression. Hum Reprod 2007; 22: 1161-1167.

54. Forbes K, Hurst LM, Aplin JD, and Westwood M. Statins are detrimental to
human placental development and function; use of statins during early
pregnancy is inadvisable. J. Cell Mol Med 2008; 12:2295-2296.

55. Graham CH, Hawley TS, Hawley RG, MacDougall JR, Kerbel RS, et al.
Establishment and characterization of first trimester human trophophoblast
cells with extended lifespan. Exp Cell Res 1993; 206: 204-211.

56. Chamley LW, Duncalf AM, Konarkowska B, Mitchell MD, and Johnson PM:
Is interleukin-3 important in antiphospholipid antibody-mediated pregnancy
failure? Fertil Steril 2001; 76: 700-706

50
57. Chamley LW, Duncalf AM, Konarkowska B, Mitchell MD, and Johnson PM:
Conformationally altered beta 2-glycoprotein I is the antigen for anticardiolipin autoantibodies. Clin Exp Immunol 1999; 115:571-576

58. Grill S, Rusterholz C, Zanetti-Dallenbach R, Tercanli S, Holzgreve W, et al.
Potential markers of preeclampsia – a review. Reproductive Biology and
Endocrinology 2009; 7: 70-84.

59. Masoura S, Kaloginnaidis IA, Gitas G, Goutsioulis A, Koiou E, et al.
Biomarkers in preeclampsia: A novel approach to early detection of the
disease. Journal of Obstetrics and Gynecology 2012; 32: 609-616.

60. Ahmed A, Singh J, Khan Y, Seshan SV and Girardi G. A new mouse model to
explore therapies for preeclampsia. PLoS One 2010; 5(10): e13663

61. Singh J, Ahmed A and Girardi G. Role of complement component C1q in the
onset of preeclampsia in mice. Hypertension 2011; 58: 716-724.

62. Clark EAS, Silver RM, and Ware Branch D. Does antiphosholipid antibodies
cause preeclampsia and HELLP syndrome? Current Rheumatology Reports
2007; 9: 219-225.

51
63. Practice Bulletin. Antiphosphosholipid syndrome. Obstet. & Gynec. 2012;
120(6): 1514-1521.

64. Redecha P, Franzke CW, Ruf W, Mackman N, and Girardi G. Neutrophil
activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in
a mouse model of antiphospholipid syndrome. J Clin Invest 2008; 118(10):
3453-3461

65. Ahmed A. New insights into the etiology of preeclampsia: identification of
key elusive factors for the vascular complications. Thromb Res 2011; 127 (3):
S72-75.

66. McKenney JM. Pharmacologic characteristics of statins. Clin. Cardiol. 2003; 26
(suppl. III): 32-38.

67. Matsumoto M, Einhaus D, Gold ES and Aderem A. Simvastatin augments
lipopolysaccharide-induced proinflammatory responses in macrophages by
differential regulation of the c-Fos and c-Jun transcription factors. J Immunol
2004; 172: 7377-7384.

52
68. Yilmaz A, Reiss C, Weng A, Cicha I, Stumpf C, et al. Differential effects of
statins on relevant functions of human monocyte-derived dendritic cells. J
Leukoc Biol 2006; 79: 529-538.

69. Kuijk LM, Beekman JM, Koster J, Waterham HR, Frenkel J, et al. HMG-CoA
reductase inhibition induces IL-1beta release through Rac1/PI3K/PKBdependent caspase-1 activation. Blood 2008; 112: 3563-3573.

